Jean-Christophe Renondin - Aug 9, 2023 Form 3 Insider Report for AgeX Therapeutics, Inc. (AGE)

Role
Director
Signature
/s/Jean-Christophe Renondin
Stock symbol
AGE
Transactions as of
Aug 9, 2023
Transactions value $
$0
Form type
3
Date filed
8/21/2023, 04:40 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGE Option to Purchase Common Stock Aug 9, 2023 Common Stock 25.8K $0.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options will vest in quarterly installments based upon Dr. Renondin's continued service as a director, with options to purchase 9,571 scheduled to vest on September 30, 2023 and options to purchase 16,250 shares scheduled to vest on December 31, 2023.